Roche Alecensa gets USFDA nod for ALK-positive early-stage lung cancer
Basel: Roche has announced that the U.S. Food and Drug Administration (FDA) has approved Alecensa (alectinib) for adjuvant treatment following tumour resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) ( …